Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit

Breast Journal

Volumn 12, Issue 6, 2006, Pages 531-535

  Kurian, Sobha ^a   Qazilbash, Muzzafar ^a   Fay, Joseph ^b,c   Wolff, S ^a   Herzig, Roger ^d,e   Hobbs, Gerry ^a   Bunner, Pam ^a   Weisenborn, Robin ^a   Aya ay, Melanie ^a   Lynch, Joseph ^a   Ericson, Solveig ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e North American Marrow Transplant Group (NAMTG)   (United States)

Author keywords

Autologous transplant; Breast cancer; High dose chemotherapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; THIOTEPA;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 33750625208     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2006.00341.x     Document Type: Article

References (16)

1. Nieto Y, Jones RB, Shpall EJ. High-dose chemotherapy for breast cancer: is another look warranted. Curr Opin Oncol 2004;16:114-9.
2. Farquhar C, Baser R, Hetrick S, Letaby A Marjoribanks J. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev, 2003;CD:D003142.
3. Tartarone A, Romano G, Galasso R, et al. Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of published data. Bone marrow transplantation 2003;31:525-30.
4. Antman KH. Randomized trials for high dose chemotherapy for breast cancer. Biochim Biophys Acta 2001;1471(3): M89-M91.
5. Montemurro F, Rondon G, Munsell M, et al. Predicting outcome basis on Swenerton score in patient's with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implication on patient selection. Biol Blood Marrow Transplant 2003;9:330-40.
6. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-18.
7. Rowlings PA, Williams SF, Antman KH, et al. Factors correlated with progression free survival after high dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999;282:1335-43.
8. Roche H, Viens P, Biron P, Lotz JP. Asselain B. High dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003;10(1): 42-7.
9. Bojko P, Welt A, Schleucher R, et al. High dose chemotherapy with autologous stem cell transplantation for patients with oligometastatic breast cancer. Bone Marrow Transplant 2004:34;637-43.
10. Guarneri V, Bengala C, Orlandini C, et al. Her-2 neu overexpression as a prognostic factor in metastatic breast cancer patients treated with high dose chemotherapy and autologous support. Bone Marrow Transplant 2004;34:413-7.
11. Kim YS, Konoplev SN, Montemurro F, et al. Her-2 neu over expression as a poor prognostic factor for patients with metastatic breast cancer undergoing high dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 2001;7:4008-12.
12. Bewick M, Conlon M, Gerard S, et al. Her-2 neu expression is a prognostic factor in patients with metastatic breast cancer treated with combination of high dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 2001;27:847-53.
13. Nieto Y, Franklin WA, Jones RB, et al. Prognostic significance of occult tumor cells in apheresis product of patients with advanced breast cancer receiving high dose chemotherapy and hematopoietic progenitor cell support. Biol Blood Marrow Transplant 2004;10:415-25.
14. Damon LE, Hu WW, Stockerl-Goldstein KE, et al. High dose chemotherapy and stem cell rescue for breast cancer: experience in California. Biol Bone Marrow Transplant 2000;6:495-505.
15. Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high dose chemotherapy for breast cancer. Haematologica 2003;88(2):201-11.
16. Dicato M. High dose chemotherapy in breast cancer: where are we now? Semin Oncol 2002;29(3 Suppl. 8):16-20.